Purpose: Benign prostatic hyperplasia (BPH) is a histologic diagnosis describing
proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The …

Background Androgenetic alopecia (AGA) is the most common cause of hair loss, often
challenging to treat. While oral finasteride (1 mg/d) is an FDA-approved treatment for male …

Garrod's concept of 'chemical individuality'has contributed to comprehension of the
molecular origins of human diseases. Untargeted high-throughput metabolomic …

Background Oral finasteride is a well‐established treatment for men with androgenetic
alopecia (AGA), but long‐term therapy is not always acceptable to patients. A topical …

Introduction Benign prostatic hyperplasia (BPH) is one of the most common diseases
affecting men and can present with bothersome lower urinary tract symptoms (LUTS) …

Purpose: The purpose of this American Urological Association (AUA) Guideline amendment
is to provide a useful reference on the effective evidence-based management of male lower …

Background Cyclin-dependent kinase (CDK)-4/6 inhibitors have been associated with
dermatologic reactions, especially alopecia, in pivotal trials. Objective We aimed to …

Finasteride and dutasteride, synthetic 5α-reductase inhibitors (5ARIs) are recommended in
many guidelines for the treatment of benign prostatic hyperplasia/lower urinary tract …

Importance In recent decades, there has been increased interest in the possible adverse
neurological effects of 5α-reductase inhibitors (5-ARIs), which have been used mainly for …

The current document summarizes the state-of-the-art knowledge as it relates to
management of male lower urinary tract symptoms (MLUTS) secondary to benign prostatic …